Please assess the completion status of the following clinical trial:

Trial Title: Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria~* Diagnosis of advanced malignancy, nonsmall-cell lung cancer (NSCLC) only during stage 1 of accrual.~* Nonsynonymous mutation of B-RAF or DDR2, defined as follows:.~  i) NSCLC with inactivating B-RAF mutation.~ii) NSCLC with discoidin domain receptor 2 (DDR2) mutation.~iii) Malignancy of other histology with DDR2 mutation or inactivating B-RAF mutation, or NSCLC having a B-RAF mutation that is not functionally characterized.~* At least 1 target lesion per Response Evaluation Criteria in Solid Tumors, vol 1.1, on baseline staging evaluation.~* Disease progression after ≥ 1 prior treatment regimen.~Exclusion Criteria~* Pleural or pericardial effusion, Grade \>1.~* QTcF \>470 msec (Grade ≥2) or diagnosed congenital long QT syndrome.~* Absolute granulocyte count \<1500/mm\^3.~* Hemoglobin level \<10 g/dL.~* Platelet count \< 75,000/mm\^3.~* Serum calcium level \<institutional lower limit of normal.~* Hypokalemia, hypophosphatemia, or hypomagnesemia, Grade \>1, despite supplementation.~* Creatinine \>3\*institutional upper limit of normal (ULN).~* Total bilirubin level \>1.5\*ULN.~* Alanine transaminase level \>3\*ULN.~* Other protocol-defined Inclusion/Exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation) (Type: EXPERIMENTAL): Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
- Dasatinib, 140 mg (NSCLC With DDR2 Mutation) (Type: EXPERIMENTAL): Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred

Based on this trial design, predict the completion outcome and termination type (if applicable).